CTD²: Cancer Target Discovery and Development

CTD2 bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. It specializes in computational and functional genomics approaches critical for translating next-generation sequencing data, as well as high-throughput and high content small molecule and genetic screens.

Banner for CTD squared program. Links to CTD squared program page
Last updated: January 12, 2018

News & Publications

previousnext
CTD²
May 23, 2018

Protein complexes are assemblies of subunits that have co-evolved to execute one or many coordinated functions in the cellular environment. Functional annotation of mammalian protein complexes is critical to understanding biological processes, as well as disease mechanisms. Here, we used genetic...

CTD²
May 22, 2018

T- and NK-cell lymphomas (TCL) are a heterogenous group of lymphoid malignancies with poor prognosis. In contrast to B-cell and myeloid malignancies, there are few preclinical models of TCLs, which has hampered the development of effective therapeutics. Here we establish and characterize...

Graphical Abstract from Peng et al., 2018.
CTD²
May 14, 2018

Adenosine (A) to inosine (I) RNA editing introduces many nucleotide changes in cancer transcriptomes. However, due to the complexity of post-transcriptional regulation, the contribution of RNA editing to proteomic diversity in human cancers remains unclear. Here, we performed an integrated...

Histopathologic image illustrating well differentiated squamous cell carcinoma in the excisional biopsy specimen. Hematoxylin-eosin stain.
CTD²
May 11, 2018

Purpose: The WEE1 tyrosine kinase regulates G2/M transition and maintains genomic stability, particularly in p53-deficient tumors which require DNA repair after genotoxic therapy. There is a need to exploit the role of WEE1 inhibition in head and neck squamous cell carcinoma (...

Graphical Abstract from McMillan et al., 2018.
CTD²
May 03, 2018

Diversity in the genetic lesions that cause cancer is extreme. In consequence, a pressing challenge is the development of drugs that target patient-specific disease mechanisms. To address this challenge, we employed a chemistry-first discovery paradigm for de novo identification of druggable...

O
O
O
O
O